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ABSTRACT 
Prostate cancer is the most common form of cancer affecting men in the Western world. Risk factors include ageing, 
genetics, recurrent inflammation, lifestyle and diet intake, related to an increase of oxidative stress. Prostate cancer risk 
is also associated with exposure to carcinogen such as polycyclic aromatic hydrocarbons (PAHs), originated from the 
incomplete combustion of carbon-containing fuels like tobacco, wood, diesel, or charbroiled meat. Although numerous 
studies have associated the effect of PAHs to tumour development, few investigations have associated its effects to 
cancer progression. Considering that prostate cancer patients don’t die from localized prostate cancer but from advanced 
disease, we are interested in investigating whether PAHs may potentially influence prostate cancer progression and how 
this could be related to an increase in oxidative stress. Likewise we evaluated the effect of PAHs (pyrene, benzo(a) 
pyrene, chrysene and benzo(k)fluoranthene) on cell growth and in the expression of molecules involved in cancer me- 
tastization such as the vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF) using prostate- 
derived cell lines from localized adenocarcinoma (HPV10), bone metastasis (PC3) and in non-neoplastic prostate epi- 
thelium cells. Moreover, we evaluated oxidative stress parameters, assessing reactive oxygen species (ROS) production 
and reduced glutathione content. Our data clearly demonstrates that PAHs can stimulate cell growth, particularly in lo- 
calized cancer cells and induce an increase of VEGF and HIF expression. These results are concomitant with an increase of 
ROS production, suggesting that PAHs exposure may participate in prostate cancer progression, in part, due to an increase 
of ROS. Therefore this study suggests that PAHs exposure should be avoided to prevent prostate cancer progression. 
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1. Introduction 
Prostate cancer remains the most frequently diagnosed 
malignancy and the second leading cause of cancer-re- 
lated mortality among males in the Western countries [1]. 
Risk factors include ageing, genetics, recurrent inflame- 
mation, lifestyle, and diet intake, most of them related to 
an increase of oxidative stress (OS) (for review see Nel- 
son et al. [2], deMarzo et al. [3], Minelli et al. [4] which 
results from the imbalance between Reactive Oxygen 
Species production (ROS) and antioxidant defences. 
Oxidative stress is also associated with prostate cancer 
progression [5]. ROS are mainly counteracted by the up 
regulation of reduced glutathione (GSH) that is the most 
abundant redox balance buffer. On the other hand, the 
increase of the antioxidants defenses may be related to 
prostate cancer survival and resistance to therapy [6,7]. 
Prostate cancer risk is also associated with carcinogen 
exposure as polycyclic aromatic hydrocarbons (PAHs), 
an environmental widespread contaminants resultant 
from the incomplete combustion of carbon-containing 
fuels such as diesel tobacco, wood, or charbroiled meat 
(for review see Nelson et al. [2]). PAHs like, ben- 
zopyrene, is listed by the International Agency for Can- 
cer Research on cancer (IARC) as a group-1 carcinogen, 
i.e. carcinogenic to humans [8,9]. These molecules may 
be associated with an increase of ROS [10-12] that may 
overcome the protection afforded by antioxidant defence 
mechanisms. It leads to biomolecules oxidative damage 
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including DNA, proteins and lipids, supporting the hy- 
pothesis that PAHs are significant contributors to geno- 
toxicity and carcinogenicity and to the disturbance of 
several signal and metabolic pathways, in prostate cancer 
(For review see Pelicano et al. [13] and Clerkin et al. 
[14]). PAHs also induce CpG island sequences methyla- 
tion of the antioxidant defence Glutathion-S-Transferase 
(GST) [15] resulting in GST depletion. These authors 
also found a significant correlation of the CpG hyper- 
methylation status with PAHs exposure through cigarette 
smoking, in prostate cancer patients. 
PAHs also induce the activation of an aryl hydrocar- 
bon receptor (AhR) that translocates to the nucleus and 
binds to DNA in dioxin-response elements, leading to the 
transcription of target genes. These target genes include a 
group of metabolizing enzymes such as cytochrome P450 
(CYP450) that catalyses the oxygenation of PAHs into 
electrophilic molecules originating the formation of DNA 
adducts [16]. However, the role of PAHs on prostate 
cancer progression remains poorly understood. Haque et 
al. [17] demonstrated that PAHs, especially benzo(a) 
pyrene, can stimulate the increase in metalloproteinase-9 
expression, a protease involved in the metastization of 
prostate cancer cells. Other main molecules involved in 
cancer metastization include the heterodimer transcript- 
tion factor HIF-1 (hypoxia-inducible factor) and the vas- 
cular endothelial growth factor VEGF. HIF-1 is com- 
posed by the HIF1-1α and HIF-1β subunits and is par- 
ticularly important in the hypoxia environment of solid 
tumours [18] promoting genes involved in hypoxia ad- 
aptation. HIF also activates genes that participate in can- 
cer cell growth and invasion, glucose metabolism, cell 
survival and angiogenesis, as VEGF [18,19], which is 
necessary for the formation of new blood vessels during 
tumour metastization (for review see Nicholson et al. 
[20] and Fulda et al. [21]). Lekas et al. [22] observed an 
increase of HIF and VEGF in prostate cancer biopsies 
when compared with those from prostate benign hyper- 
plasia. The aim of is study was to evaluate whether PAHs 
(pyrene, benzo(a)pyrene, chrysene and benzo(k)fluoran- 
thene) may potentially influence prostate cancer progres- 
sion and how this could be related with an increase of 
oxidative stress. Likewise we evaluated the effect of 
PAHs on prostate cancer cell growth, in the expression of 
molecules involved in cancer metastization as the vascu- 
lar endothelial growth factor (VEGF) and the hypoxia 
inducible factor (HIF) and on oxidative stress parameters, 
using a cell line model representing prostate cancer car- 
cinogenesis. 
2. Materials and Methods 
2.1. Cell Culture Conditions and Reagents 
Human prostate cancer cell lines derived from localized 
adenocarcinoma (HPV10 cells) [23], bone metastasis 
(PC3 cells) [24] and non-neoplastic prostate epithelium 
(RWPE1 cells) [25] were purchased from the American 
Type Culture Collection (ATCC) and cultured in opti- 
mum growth conditions. 
RWPE1 and HPV10 cells were grown in keratinocytes 
medium (Gibco) supplemented with 5 ng/ml of human 
recombinant epidermal growth factor (rEGF) (Gibco) 
and 0.05 mg/ml of bovine pituitary extract (BPE) (Invi- 
trogen, formely Gibco-BRL). PC3 cells were grown in 
RPMI 1640 medium (Sigma) with 10% (v/v) heat-inac- 
tivated fetal bovine serum (FBS) (Biochrom) and 2 mM 
L-glutamine (Sigma). 
Both medium, were supplemented with 100 U/ml 
Penicillin, 100 μg/ml Streptomycin and with 5 μg/ml 
Kanamycin (Sigma). 
Cells were maintained in a 95% humidified incubator 
with 5% CO2 at 37˚C and were treated with 100 μM 
CoCl2 for hypoxia experiments. Cells were passaged 
with trypsinization every fourth day. For the assays, 
RWPE1 and HPV10 cells were plated at a density of 5 × 
105 cells/ml whereas PC3 cells were seeded at 3 × 105 
cells/ml. 
After being cultured up to 80% confluence, cells were 
washed once with fresh assay medium and treated for 24 
to 72 hours with the polycyclic aromatic hydrocarbons 
(PAHs) namely, pyrene, benzo(a)pyrene, chrysene and 
benzo(k)fluoranthene (10 nM - 100 μM). PAHs, pur- 
chased from Sigma Aldrich were solubilized in dimethy- 
lsulfoxide (DMSO). Culture conditions and control con- 
tained 1% (v/v) DMSO. 
2.2. Cell Proliferation Evaluation 
Cell proliferation was evaluated by the MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(Sigma) assay that quantifies the reduction of the yellow 
tetrazolium salt to purple formazan crystals by the mito- 
chondria of viable cells. Briefly, untreated and treated 
cells were washed with PBS (Gibco) that was replaced 
by MTT (0.5 mg/ml) supplemented with 1 mM CaCl2 
(Sigma). The cells were then incubated at 37˚C for 2 
hours. Formazan crystals were dissolved with HCl 0.04M 
in isopropanol. Absorbance from the resultant coloured 
solution was measured at 570 nm [7,26]. 
To each well was added 0.1 ml of HCl 0.04 M, in iso- 
propanol, in order to dissolve the formazan crystals. Ab- 
sorvance from the resultant colored solution was meas- 
ured at 570 nm. 
2.3. Flow Cytometry Studies 
Flow cytometry studies were performed to evaluated 
ROS (peroxides), HIF and VEGF expression levels, ac- 
cording to the following protocol: after 24 h incubation, 
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1 × 106 cells and corresponding controls were collected 
by trypsinization and washed two times in PBS buffer by 
centrifugation for further acquisition and analysis in a 
FACScalibur (488 nm and 635 nm), using the Cellquest 
and Paint-a-gate software (BD Bioscience). At least 10,000 
events were collected for peroxides, HIF and VEGF de- 
terminations. 
2.3.1. HIF and VEGF Expression Levels Evaluation 
HIF and VEGF evaluation were performed after labeling 
with monoclonal antibodies. 
Firstly, 1 × 105 cells were permeabilized and fixed 
with 250 μl of cytofix-cytoperm (Cytofix/cytoperm 
kit, Pharmigen) for 20 min at 4˚C, washed with perm- 
wash (Cytofix/cytoperm kit), and centrifuged 2 times 
at 300 ×g for 5 minutes. For VEGF detection, cells were 
labeled with 10 μl of a 25 μg/ml stock solution of a 
monoclonal antibody anti-human VEGF conjugated with 
phycoerythrin (purchased from R&D systems), incubated 
for 45 minutes in the dark at room temperature and 
washed two times with PBS, at 300 ×g. For HIF detec- 
tion, cells were labeled with 10 μg/ml of an antibody anti- 
human/mouse HIF-1α and incubated for 20 minutes in 
the dark, at room temperature. Cells were washed two 
times with PBS, at 300 ×g and ressuspended in 200 μl 
PBS. Then, cells were stained with 10 μl of a 25 μg/ml 
stock solution of a goat antibody anti-mouse IgG-con- 
jugated with Phycoerytrin, followed 20 minutes in the 
dark at room temperature. After two wash steps, cells 
were ressuspended in 500 μl PBS and immediately ana- 
lyzed by flow cytometry. 
2.3.2. Reactive Oxygen Species (ROS) Measurements 
Intracellular levels of peroxides were performed labelling 
5 × 105 cells with 5 μM 2,7-dichlorofluorescein diacetate 
(DCFH2-DA) (Sigma) according to Rothe and Valet [27] 
with adaptations [26]. Cells were than incubated during 1 
hour at 37˚C, in the dark, washed 2 times in 0.5 ml phos- 
phate-buffered saline (PBS), ressuspended in 0.5 ml PBS 
and immediately analysed by flow cytometry [7,26]. This 
methodology is based on the conversion of (DCFH2-DA) 
in DCFH2 by intracellular esterases and consequent for- 
mation of the highly fluorescent probe 2,7 dichlorofluo- 
rescein (DCF) by ROS that is proportional to the intra- 
cellular levels of ROS, upon excitation at 488 nm. 
2.4. Reduced Glutathione (GSH) Assay 
2.4.1. Cell Lysates Preparation 
After 24 h, treated cells were washed 2 times with PBS, 
scraped off the flasks and resuspended in 1ml PBS. Cells 
were then submitted to 3 sonication pulses for 10 seconds 
with 1 minute intermittent cooling on ice, in a Bandelin 
Sonorex. 
Protein concentration was assessed using the bicin- 
chonic acid assay kit (Sigma) according to manufacture’s 
instructions. The lysates had been stored at −80˚C before 
usage. 
2.4.2. GSH Determination 
GSH was performed using a kit from OxisResearch ac- 
cording to manufacture’s instructions. This method is 
based on the formation of a chromophoric thione that is 
proportional to GSH concentration at 420 nm [7,26]. 
2.4.3. Statistics 
Statistical analyses were carried out using t-test. Signifi- 
cance was assumed for p values < 0.05. 
3. Results 
3.1. PAHs Exposure Induces Cell Proliferation 
RWPE1, HPV10 and PC3 cells were treated with PAHs 
namely, pyrene, benzo(a)pyrene, chrysene and benzo(k) 
fluoranthene at doses of 10 nM, 100 nM and 1 μM for 72 
h. Results show that environmental PAHs concentrations 
transiently enhance the proliferation rate in the pros- 
tate-derived cell lines RWPE1 (non-tumour), HPV10 
(localized carcinoma) and PC3 (metastatic carcinoma), 
with maximum effect on HPV10 cells suggesting a tu- 
mour-growth inducing capacity of PAHs, which could 
influenced cancer progression (Figure 1). 
Cell proliferation effect was induced in a concentration, 
time exposure, cell type and compound dependent man- 
ner (Figure 1). Here, PAHs induced cell growth, during 
48 h incubation. However, in RWPE1 cells, maximum 
effect was reached at 24 h treatment. When PAHs expo- 
sure was extended more than 48 h, a decrease in cell 
growth was observed in non-malignant RWPE1 cells. 
Moreover, PAHs induced less effect in these cells. In 
HPV10 cells the maximum effect was found at 48 h in- 
cubation in the presence of pyrene. Chrysene generally 
shows a lower effect on cell growth. Oppositely, benzo(k) 
fluoranthene induced a prolonged effect on HPV10 cells. 
3.2. VEGF and HIF Expression Induced 
Following PAHs Treatment 
Considering that HIF and VEGF participation are fun- 
damental keys for cancer metastization we performed 
flow cytometry studies to assess VEGF and HIF expres- 
sion. As hypoxia environment is a frequent condition of 
solid tumours that require HIF participation and cones- 
quently VEGF action for angiogenesis, it was considered 
important to evaluate HIF and VEGF expression, also un- 
der hypoxia. Here, we found that malignant cells, particu- 
larly the metastatic PC3 cells, show higher HIF and VEGF 
basal expression, in hypoxia and normoxia, comparing to            
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Figure 1. Dose-response curves. Effect of polycyclic aromatic hydrocarbons (PAHs) (pyrene, benzo(a)pyrene, chrysene and 
benzo(k)fluoranthene) concentrations (10 nM 100 nM and 1 μM) on the proliferation of human non-malignant prostate epi-
thelium (RWPE1) and prostate cancer cells, derived from localized (HPV10) and metastatic carcinoma (PC3). Results are 
expressed as percentage of MTT reduction relatively to control (treated cells with 1% v/v DMSO) and correspond to the 
ean ± SD of at least 3 separate experiments. m   
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non-malignant RWPE1 cells (Figure 2(a)). However, 
after PAHs treatment, HIF and VEGF expression gener-
ally increased, and particularly augmented in the HPV10 
(localized cells) comparing to untreated cells (Figure 
2(b)). 
Hypoxia condition was associated to a several increase 
of HIF and VEGF expression in the localized cancer cells, 
HPV10, in the presence of BP (Figure 2(b)). However 
an opposite effect was observed in the non-malignant 
cells, RWPE1. Moreover, these cells are less sensitive to 
an increase of VEGF and HIF after PAHs treatment. 
Figure 3 reinforces the effect of PAHs on HIF and  
VEGF expression, under hypoxia conditions. Therefore, 
we observed a several increase in HIF and VEGF ex-
pression in HPV10 after BK and BP treatment, in hy-
poxia comparing to normoxia. However, this effect was 
not observed in the PC3 cells. In hypoxia basal condi-
tions, HIF was several increased in all the cell lines, par-
ticularly in PC3. 
3.3. Increase of ROS May Be Associated with 
PAHs Effects 
We also investigated whether PAHs could trigger an 
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Figure 2. VEGF and HIF expression. (a) Basal levels of VEGF and HIF on HPV10 and PC3 cells comparing to RWPE1. 
VEGF and HIF expression was evaluated in normoxia and in hypoxia conditions in untreated cells. (b) Effect of PAHs on 
VEGF and HIF expression. VEGF and HIF expression were evaluated following 24 h PAHs treatment, at concentrations that 
potentiate cell growth (100 nM benzo(k)fluoranthene (BK), 1 μM benzo(a)pyrene (BP) for HPV10 and 100 nM for the other 
cells lines, respectively), in normoxia and in hypoxia conditions. Data are expressed as the mean ± SD of at least 3 experi-
ments. Significantly differences are considered for *p < 0.05, vs control (cells treated with 1% v/v DMSO). 
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Figure 3. Effect of hypoxia on VEGF and HIF expression. VEGF and HIF expression was evaluated in normoxia and in hy-
poxia conditions, in cells treated with PAHs for 24 h, at concentrations that potentiate cells growth (100 nM benzo(k) 
fluoranthene (BK), 1 μM benzo(a)pyrene (BP) for HPV10 and 100 nM for the other cells lines, respectively). Data are ex-
pressed as the mean ± SD of at least 3 experiments. Significantly differences are considered for *p < 0.05, vs normoxia condi-
tions. 
 
increase of ROS (peroxides) associated to tumour devel- 
opment and progression. These results show that cell 
growth and the increase of HIF and VEGF expression are 
accomplished by an increase of ROS (Figure 4) in 
HPV10 and RWPE1 cells but not in PC3. Comparative 
study within the same experimental series revealed that 
metastatic cell line already shows very high basal levels 
of ROS [7]. Moreover we found that the increase of ROS 
under PAHs treatment is not counteracted by an increase 
of the reduced glutathione (GSH) defence. However, 
GSH basal levels are several increased in the PC3 cells 
(Figure 5). 
4. Discussion 
Conventional therapy of prostate cancer produces a high 
rate of cure for patients with localized disease, however, 
a cure to metastatic disease isn’t yet achieved. Therefore 
is important to identify compounds which exposure may 
contribute for prostate cancer metastization. Although 
polycyclic aromatic hydrocarbons (PAHs) have been 
related to cancer development, in general, few investiga- 
tions have addressed PAHs effects on prostate cancer 
progression. Here we found that environmental concen- 
trations of PAHs [28-30] stimulate cell growth in a con- 
centration, exposure time, cell type and compound de- 
pendent manner (Figure 1). This effect was particularly 
pronounced in the localized cancer cells HPV10. There- 
fore these results suggest that PAHs exposure may trig- 
ger an important role in the earliest stages of prostate 
cancer growth. Plísková et al. [31] found an increase in 
the growth of the breast cancer cell line MCF-7 in the 
presence of PAHs, namely BP, and demonstrated that it 
was mediated by the estrogen receptor. In fact, estrogen 
receptors may be expressed in benign and malignant 
prostate epithelial cells [32,33]. PAHs may also interact 
with androgen receptor as agonists [34]. It is well known 
that most prostate cancers are dependent on androgen 
stimulation mediated by the androgen receptor for cell 
growth and survival. Moreover, androgens may also in- 
duce ROS increment [35]. However, during prostate 
cancer progression other mechanisms may contribute to 
androgen receptor activity like androgen receptor over- 
expression, mutations or genomic amplification. These 
genetic alterations are responsible for a highly androgen 
receptor sensitivity in response to androgens, antiandro- 
gens or nonandrogenic hormones, conferring a selective 
growth advantage to prostate cancer cells [36]. Never- 
theless, bypassing the androgen receptor pathway, asso- 
ciated to androgen-independence, may be also achieved 
as an alternative mechanism for prostate cancer survival 
[37]. In fact, we found that HPV10 and PC3 don’t ex- 
press androgen receptor (data not shown). Moreover, 
Besides, ROS overproducti n frequently induces cell  o  
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Figure 4. Effect of hypoxia on VEGF and HIF expression. VEGF and HIF expression was evaluated in normoxia and in 
hypoxia conditions, in cells treated with PAHs for 24 h, at concentrations that potentiate cells growth (100 nM benzo 
(k)fluoranthene (BK), 1 μM benzo(a)pyrene (BP) for HPV10 and 100 nM for the other cells lines, respectively). Data are ex- 
pressed as the mean ± SD of at least 3 experiments. Significantly differences are considered for *p < 0.05, vs control (cells 
treated with 1% v/v DMSO). 
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Figure 5. PAHs effect on GSH content. Cells lines, namely RWPE1, HPV10 and PC3 were treated with PAHs at concentra-
tions that potentiate cell growth (100 nM benzo(k)fluoranthene (BK), 1 μM benzo(a)pyrene (BP) for HPV10 and 100 nM for 
the other cells lines, respectively), for 24 hours as described in materials and methods. Results are expressed in μmol/g pro-
tein and represent the means ± SD of at least triplicate determinations.  
 
death instead of proliferation, it is now generally ac-
cepted a ROS association to invasiveness and metastiza-
tion [5,7,38]. Moreover, ROS play an essential role in 
signal transduction pathways [39], cell cycle progression 
[40] or gene transcription [41]. It also promotes DNA 
oxidation that is mainly responsible for DNA mutations 
favouring tumour progression (For review see Nelson et 
al. [2] Clerkin et al. [14]). We previously report that low 
levels of ROS (10 nM - 100 nM peroxides) induced pro-
liferation of the HPV10 cells [7]. Here we found that the 
increase of ROS mediated by PAHs observed in HPV10 
and RWPE1 cells may be associated with the growth of 
these cells lines, but not with PC3 cells that maintain 
ROS levels (Figure 4). We also observed that the in-
crease of ROS was not counteracted by an increase in the 
GSH content (Figure 5), suggesting that ROS increment 
may have not reached the necessary levels to recruit GSH 
and/or that these cells couldn’t increase GSH. On the 
other hand, a higher GSH content was observed in PC3 
(Figure 5) and was concomitant with higher intrinsic 
ROS levels (Figure 4), also reinforcing that ROS par-
ticipate on prostate cancer progression. Besides that, data 
not show also indicate that toxic PAHs concentrations 
(100 μM) are associated to GSH depletion. Moreover, 
other antioxidant defences may counteract the potential 
toxicity of PAHs and induced ROS as GST, known by its 
role in PAHs detoxification [42]. On the other hand HIF 
and VEGF expression are crucial conditions for prostate 
cancer invasion and metastasis. HIF activates genes in-
volved in cancer cell growth, invasion survival and an-
giogenesis like VEGF [18,19]. This molecule plays a 
major role in angiogenesis necessary for tumour metasti-
zation by promoting the formation of new blood vessels 
(For review see Nicholson et al. [20]. As expected, PC3 
show a higher HIF and VEGF expression at basal condi-
tions (Figure 2(a)). Also the hypoxia effect on the HIF 
expression was more pronounced in these cells. However, 
in the presence of PAHs we observed an increase in the 
HIF and VEGF expression that was more pronounced in 
HPV10 (Figure 2(b)), once reinforcing the role of such 
Copyright © 2013 SciRes.                                                                                  JCT 
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substances in the earliest stages of prostate cancer me-
tastization. Other studies performed by Haque et al. [17] 
demonstrated that benzo(a)pyrene can stimulate the pro-
duction of the metalloproteinase-9 in human prostate 
cancer cells, an enzyme involved in matrix dissolution, a 
process required for tumour cells to cross the basement 
membrane and extend from the primary site. 
Here we found that environmental PAHs concentra-
tions may induce the production of ROS (Figure 4) at 
levels that may contribute for cell growth, particularly in 
the localized cancer cells and also induce the expression 
of HIF and VEGF that participate in invasiveness and 
metastization. Therefore this study offers important in-
formation concerning the tumour-inducing progression 
(pro-metastatic) capacity of PAHs. Additional studies 
should be directed in order to evaluate PAHs concentra-
tions, which reach prostate gland. Nevertheless we also 
should take into account that PAHs may induce a cumu-
lative effect in the human tissues and therefore the expo-
sure to PAHs should be also avoided to prevent prostate 
cancer progression. It would also be interesting to inves-
tigate whether in vitro migration/invasion properties of 
HPV10 (localized carcinoma-derived) cells would be 
stimulated under treatment with PAHs. 
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